Analyst Price Targets — TLSI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 13, 2026 12:41 pm | — | Lake Street | $8.00 | $2.37 | TheFly | TriSalus Life Sciences price target lowered to $8 from $10 at Lake Street |
| November 15, 2024 12:04 pm | William Plovanic | Canaccord Genuity | $11.00 | $4.11 | StreetInsider | TriSalus Life Sciences, Inc. (TLSI) PT Lowered to $11 at Canaccord Genuity |
| September 16, 2024 6:06 am | Suraj Kalia | Oppenheimer | $10.00 | $4.52 | StreetInsider | Oppenheimer Starts TriSalus Life Sciences, Inc. (TLSI) at Outperform, PT $10 |
| July 2, 2024 5:51 am | William Plovanic | Canaccord Genuity | $12.00 | $5.33 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on TriSalus Life Sciences, Inc. (TLSI) |
Latest News for TLSI
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM eastern time to discuss its…
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ: TLSI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. ("TriSalus" or the "Company") (NASDAQ: TLSI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOS ANGELES, June 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TriSalus Life Sciences, Inc. (“TriSalus” or “the Company”) (NASDAQ: TLSI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TLSI.
U.S. House Trading
No House trades found for TLSI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.